Adipotide
In clinical trialsAlso known as: 859216-15-2, HKPao, orb1981129, EX-A6186, DA-74204, T76315
Adipotide (859216-15-2, HKPao, orb1981129) is classified under other / experimental, currently studied in clinical trials.
Read the full guide: what the research shows on Adipotide →What the research says
Aggregated from the cited literature below. We summarize sources — we don't author claims.
Adipotide is referred to in these sources as a proapoptotic peptide bioconjugate targeting adipose vascular/endothelial components in a nanoparticle-delivery context. In one comparative study, Adipotide (a bioconjugate composed of the targeting peptide and the proapoptotic component KLA) was compared with a nanoparticle-targeted therapeutic approach in diet-induced obesity (DIO) mouse models, with reported differences in body weight and related metabolic measures.
Mechanism (as reported)
A study reported that nanoparticle-targeted delivery involving a prohibitin-targeted nanoparticle (PTNP) encapsulated with a proapoptotic peptide component (KLA; described as (D)(KLAKLAK)2) aimed to target adipose vascular markers and was associated with cytoplasmic delivery into adipose endothelial cells via escape from endosomes/lysosomes. In the same study, Adipotide was described as a bioconjugate composed of the same targeting peptide and the proapoptotic component used in the PTNP approach (PMID: 23871959).
Key findings (each cites a source)
- A comparative preclinical study reported that in DIO mice, a nanoparticle-targeted proapoptotic peptide approach (KLA-PTNP) led to a reduction in body weight and decreased serum leptin levels, whereas a bioconjugate composed of the same targeting peptide and KLA (Adipotide) was not associated with these reductions in the same way in that study’s comparison. [PMID 23871959]
- The same comparative study reported anti-obesity effects on dysfunctional adipose cells (including adipocytes and macrophages) and reduced ectopic fat deposits in liver and muscle, alongside elevated serum adiponectin, with no detectable hepatotoxicity in the reported context. [PMID 23871959]
- The comparative study reported that drug delivery via PTNP accumulated in obese fat via the enhanced permeability and retention (EPR) effect and was enhanced by multivalent active targeting, with cytoplasmic delivery into adipose endothelial cells described as occurring via escape from endosomes/lysosomes. [PMID 23871959]
- A separate preclinical study reported that a proapoptotic peptide designed to induce apoptosis in white adipose tissue endothelium (HF-PP) improved glucose tolerance in obese mice in a weight- and food intake-independent manner, with decreases in serum insulin and triglycerides relative to a vehicle control in that study. [PMID 22733798]
- The same preclinical study reported microarray changes in adipose tissue pathways related to mitochondrial dysfunction, oxidative phosphorylation, and branched-chain amino acid degradation by HFD exposure and reversal by proapoptotic peptide administration. [PMID 22733798]
Independent HPLC purity tests (4)
Real third-party HPLC results aggregated from Peptigrity, each attributed to the lab that ran it — average purity 99.7% across 4 tests. Not our verdict.
Labs: liquilabs, Vanguard Laboratory.
| Vendor | HPLC purity | Lab | Date |
|---|---|---|---|
| 24peptides.com | 99.80% | liquilabs | 2026-06-22 |
| corepeptides.com | 99.80% | Vanguard Laboratory | 2026-03-31 |
| 24peptides.com | 99.50% | liquilabs | 2026-02-16 |
| certified-pep.com | 99.78% | Vanguard Laboratory | 2025-12-11 |
Research literature (5)
Consolidated from PubMed — each links to the original record.
- Preclinical efficacy of the GPER-selective agonist G-1 in mouse models of obesity and diabetes.
Sharma G, Hu C, Staquicini DI, Brigman JL, Liu M, Mauvais-Jarvis F · Science translational medicine · 2020 · PMID 31996464
- Epigenetic Age Acceleration in Adolescence Associates With BMI, Inflammation, and Risk Score for Middle Age Cardiovascular Disease.
Huang RC, Lillycrop KA, Beilin LJ, Godfrey KM, Anderson D, Mori TA · The Journal of clinical endocrinology and metabolism · 2019 · PMID 30785999
- Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J · Diabetes, obesity & metabolism · 2017 · PMID 27862873
- A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.
Hossen N, Kajimoto K, Akita H, Hyodo M, Harashima H · Journal of controlled release : official journal of the Controlled Release Society · 2013 · PMID 23871959
- Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium.
Kim DH, Sartor MA, Bain JR, Sandoval D, Stevens RD, Medvedovic M · Diabetes · 2012 · PMID 22733798
FAQ
- What is Adipotide?
- Adipotide (859216-15-2, HKPao, orb1981129) is classified under other / experimental, currently studied in clinical trials. Research goals associated with it include metabolic & weight.
- Is Adipotide FDA-approved?
- Not yet — Adipotide is investigational and currently in clinical trials.
- What does the research on Adipotide say?
- peptideone aggregates 5 references from PubMed for Adipotide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.